$11.83
2.96% today
Nasdaq, Nov 21, 08:51 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Target price 2024 - Analyst rating & recommendation

Roivant Sciences Classifications & Recommendation:

Buy
91%
Hold
9%

Roivant Sciences Price Target

Target Price $16.19
Price $11.49
Potential
Number of Estimates 8
8 Analysts have issued a price target Roivant Sciences 2025 . The average Roivant Sciences target price is $16.19. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Roivant Sciences to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2025 of . Most analysts recommend the Roivant Sciences stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Revenue Million $ 124.80 101.03
103.66% 19.05%
EBITDA Margin -847.68% -965.15%
50.58% 13.86%
Net Margin 3,073.17% -533.53%
280.85% 117.36%

8 Analysts have issued a sales forecast Roivant Sciences 2025 . The average Roivant Sciences sales estimate is

$101m
Unlock
. This is
19.62% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$170m 35.26%
Unlock
, the lowest is
$22.0m 82.50%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $125m 103.66%
2025
$101m 19.05%
Unlock
2026
$53.0m 47.58%
Unlock
2027
$71.6m 35.12%
Unlock
2028
$765m 968.62%
Unlock
2029
$1.6b 105.90%
Unlock

3 Analysts have issued an Roivant Sciences EBITDA forecast 2025. The average Roivant Sciences EBITDA estimate is

$-975m
Unlock
. This is
12.52% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-787m 29.38%
Unlock
, the lowest is
$-1.1b 3.55%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-1.1b 0.64%
2025
$-975m 7.83%
Unlock
2026
$-1.1b 11.49%
Unlock
2027
$-1.0b 7.13%
Unlock

EBITDA Margin

2024 -847.68% 50.58%
2025
-965.15% 13.86%
Unlock
2026
-2,052.73% 112.69%
Unlock
2027
-1,410.85% 31.27%
Unlock

4 Roivant Sciences Analysts have issued a net profit forecast 2025. The average Roivant Sciences net profit estimate is

$-539m
Unlock
. This is
112.99% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-477m 111.48%
Unlock
, the lowest is
$-631m 115.19%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $3.8b 468.31%
2025
$-539m 114.05%
Unlock
2026
$-931m 72.79%
Unlock
2027
$-865m 7.09%
Unlock
2028
$7.3m 100.85%
Unlock
2029
$785m 10,604.77%
Unlock

Net Margin

2024 3,073.17% 280.85%
2025
-533.53% 117.36%
Unlock
2026
-1,758.62% 229.62%
Unlock
2027
-1,209.33% 31.23%
Unlock
2028
0.96% 100.08%
Unlock
2029
49.84% 5,091.67%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Earnings Per Share $ 5.23 -0.74
468.31% 114.15%
P/E negative
EV/Sales 34.19

4 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.74
Unlock
. This is
113.07% lower
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.65 111.48%
Unlock
, the lowest is
$-0.86 115.19%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $5.23 468.31%
2025
$-0.74 114.15%
Unlock
2026
$-1.27 71.62%
Unlock
2027
$-1.18 7.09%
Unlock
2028
$0.01 100.85%
Unlock
2029
$1.07 10,600.00%
Unlock

P/E ratio

Current 2.03 129.85%
2025
-15.63 869.95%
Unlock
2026
-9.05 42.10%
Unlock
2027
-9.74 7.62%
Unlock
2028
1,149.00 11,896.71%
Unlock
2029
10.74 99.07%
Unlock

Based on analysts' sales estimates for 2025, the Roivant Sciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

34.19
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
82.79
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 27.48 57.52%
2025
34.19 24.42%
Unlock
2026
65.22 90.76%
Unlock
2027
48.27 25.99%
Unlock
2028
4.52 90.64%
Unlock
2029
2.19 51.43%
Unlock

P/S ratio

Current 66.55 4.80%
2025
82.79 24.40%
Unlock
2026
157.94 90.76%
Unlock
2027
116.89 25.99%
Unlock
2028
10.94 90.64%
Unlock
2029
5.31 51.43%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today